Patent ID: 8940493
Filing Date: 2015-01-27
Classification: A61P,G01N

Abstract:
1. A method for predicting efficacy of IGF-1R antagonist therapy in a patient, comprising the steps of: a) preparing a sample wherein a blood sample from the patient is mixed with an antibody to epithelial cell adhesion molecule (EpCAM), so as to obtain a cell population enriched for tumor cells; b) contacting the enriched cell population with an anti-cytokeratin antibody labeled with fluorescein isothiocyanate (FITC); c) contacting the enriched cell population with a phycoerythrin (PE)-labeled antibody to insulin-like growth factor receptors (IGF-1R); and d) determining the presence of cells bound by both the anti-cytokeratin antibody and the anti-IGF-1R antibody; wherein the presence of cells bound by both antibodies is predictive of efficacy of IGF-1R antagonist therapy in the patient.